Instrument Inactif

Communiqués Spectrum Pharmaceuticals, Inc.

Actions

SPPI

US84763A1088

Recherche biotechnologique et médicale

Communiqués

01/08/23	Assertio Holdings, Inc. Closes Spectrum Pharmaceuticals Transaction	AQ
27/07/23	Assertio Holdings, Inc. Announces Favorable Vote on Proposed Acquisition of Spectrum Pharmaceuticals	AQ
20/07/23	Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote “FOR” Proposed Transaction with Assertio Holdings, Inc.	BU
30/06/23	SPECTRUM PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Spectrum Pharmaceuticals, Inc. - SPPI	BU
17/05/23	Spectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement	BU
09/05/23	Spectrum Pharma: Q1 Earnings Snapshot	AQ
09/05/23	Spectrum Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update	BU
01/05/23	SPECTRUM PHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8-K)	AQ
26/04/23	SPECTRUM PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Spectrum Pharmaceuticals, Inc. - SPPI	BU
25/04/23	SPECTRUM PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
04/04/23	SPECTRUM PHARMACEUTICALS INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
04/04/23	Spectrum Pharmaceuticals : Current Corporate Presentation	PU
03/04/23	SPECTRUM PHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8-K)	AQ
31/03/23	SPECTRUM PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	AQ
22/03/23	Spectrum Pharma: Q4 Earnings Snapshot	AQ
22/03/23	Spectrum Pharmaceuticals Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Corporate Update	BU
20/03/23	Spectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update	AQ
17/03/23	Spectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update	BU
10/03/23	SPECTRUM PHARMACEUTICALS INC : Regulation FD Disclosure (form 8-K)	AQ
09/02/23	SPECTRUM PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
09/02/23	Spectrum Pharmaceuticals Receives Permanent J-Code for ROLVEDON Injection (J1449) from U.S. Centers for Medicare & Medicaid Services	AQ
08/02/23	Spectrum Pharmaceuticals Receives Permanent J-Code for ROLVEDON™ (eflapegrastim-xnst) Injection (J1449) from U.S. Centers for Medicare & Medicaid Services	BU
02/02/23	SPPI LAWSUIT ALERT: Levi & Korsinsky Notifies Spectrum Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline	PR
01/02/23	Spectrum Pharmaceuticals Provides Update on ROLVEDON Injection and Announces Unaudited Fourth Quarter 2022 Financial Results	AQ
31/01/23	Spectrum Pharmaceuticals Provides Update on ROLVEDON™ (eflapegrastim-xnst) Injection and Announces Unaudited Fourth Quarter 2022 Financial Results	BU